June 30 (Reuters) - Hong Kong-listed drug design tech firm Metis TechBio said on Tuesday it has granted U.S.-based biotechnology firm Boulevard Bio exclusive global rights to develop, manufacture and ...
METiS TechBio (7666.HK), a leading AI-driven drug delivery innovation company, today announced it has entered into an ...
Metis TechBio, a drug design tech firm listed in Hong Kong, has entered a deal with U.S.-based Boulevard Bio, granting ...
Hong Kong-listed Chinese biotech METiS TechBio has licensed global rights to its preclinical trispecific T-cell engager MTS-128 to Deerfield-backed Boulevard Bio, in a deal potentially worth more than ...
The StarPhoenix on MSN
'These youths are the future': Students celebrate bison naming ceremony
From naming to ceremony, Metis youth are helping shape bison conservation efforts in Batoche.
Metis, one of Ethereum’s earliest Layer 2 (L2) scaling solutions, is shifting its focus from pure scaling to enabling AI-native infrastructure, says CEO Tom Ngo. In a sit-down with TheStreet ...
With its exceptional adaptability amid complex geopolitical conditions and a robust trust framework, Metis Global Group ("Metis" or the "Group") has once again been recognised with the "Trustee ...
The mystery remains why the Métis would want the government’s attention, as evidence suggests Canada’s historic attempts to oversee aboriginal people have been disastrous You can save this article by ...
The Manitoba Métis Federation is accusing the provincial and federal governments of violating the constitutional right of its ...
The audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. Cort Dogniez, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results